{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-311957","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.572780+00:00","generated_at":"2026-05-16T13:49:49.923336+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced","bullets":["Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.","Repriced options originally ranged from $17.80 to $47.60; CEO Jean-Paul Kress repriced 4,164,831 options.","Retention period ends Dec 5, 2027; options exercised earlier retain original exercise price.","CFO Sandy Mahatme received option for 1,388,274 shares at $17.80, reducing to $8.18 after retention period.","Repricing aims to retain employees and avoid dilution from new equity grants or cash comp."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-311957","json":"https://secwatch.observer/filing/0001193125-25-311957.json","markdown":"https://secwatch.observer/filing/0001193125-25-311957.md","text":"https://secwatch.observer/filing/0001193125-25-311957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525311957/0001193125-25-311957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525311957/vor-20251205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:49:49.923336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}